Related Experiment Videos
Sulfisoxazole prophylaxis of middle ear effusion and recurrent acute otitis media
Insights
Sulfisoxazole prophylaxis significantly reduced acute otitis media (AOM) episodes in children under 2 years old. However, it did not decrease the occurrence of persistent otitis media with effusion.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Recurrent acute otitis media (AOM) is a common pediatric concern.
- Prophylactic antibiotic use is a strategy to manage recurrent AOM.
- Sulfisoxazole is an antibiotic considered for otitis media management.
Purpose of the Study:
- To evaluate the efficacy of sulfisoxazole prophylaxis in preventing recurrent acute otitis media (AOM) in otitis-prone children.
- To assess the impact of sulfisoxazole on persistent otitis media with effusion.
Main Methods:
- A double-blind, cross-over clinical trial involving 32 otitis-prone children.
- Comparison of sulfisoxazole therapy versus placebo over a defined treatment period.
- Monitoring of AOM episodes and persistent otitis media with effusion.
Main Results:
- Sulfisoxazole therapy resulted in significantly fewer AOM episodes (22%) compared to placebo (63%) (P = .001).
- Efficacy was statistically significant in children under 2 years of age.
- No significant difference in the frequency of persistent otitis media with effusion was observed between sulfisoxazole and placebo groups (P > .975).
Conclusions:
- Sulfisoxazole is effective in preventing recurrent symptomatic acute otitis media, particularly in younger children.
- Sulfisoxazole prophylaxis does not appear to reduce the incidence of persistent otitis media with effusion.
- Close monitoring of children on long-term sulfisoxazole for AOM prevention is recommended.
Abstract:
The efficacy of sulfisoxazole prophylaxis was evaluated in 32 otitis-prone children in a double-blind cross-over clinical trial. During the sulfisoxazole therapy, seven patients (22%) had nine episodes of acute otitis media (AOM) while 20 patients (63%) receiving placebo had 36 episodes of AOM (P = .001). Although sulfisoxazole appeared to be beneficial in patients aged 2 to 5 years, statistically significant efficacy was noted only in children under 2 years of age. Otitis media with effusion persisting for more than five weeks was observed in ten children (31%) during sulfisoxazole therapy and in 14 children (44%) during the placebo period (P greater than .975). Sulfisoxazole therefore appears effective in preventing recurrent symptomatic AOM but not in reducing the frequency of persistent otitis media with effusion. The importance of careful follow-up of children receiving long-term sulfisoxazole therapy for prevention of recurrent AOM is stressed.